Device Trial Radar · NCT06948331
RADA16 for Aquablation Day Case
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 14, 2026
Primary completion
Sep 17, 2026
Study completion Oct 21, 2026
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge. The primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation. The secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).
Conditions
- Hematuria
- Benign Prostatic Hyperplasia
- Lower Urinary Tract Symptoms
Interventions
PuraStatDevice
Sterile gel composed of synthetic peptide and sterile water; provided as a prefilled syringe. The will be applied to the inside of the prostate to help stop bleeding following Aquablation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Discharged the Same Day as AquablationTime frame: Day 1 (Operative Visit)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.